Core Insights - The core competitive advantage of companies in the biopharmaceutical industry has shifted from singular technological breakthroughs to the ability to accurately predict frontier trends, diversify pipeline layouts, and construct an innovative ecosystem across the entire industry chain [1][3]. Company Overview - Boya Life has been recognized for its significant breakthroughs in the field of cells and exosomes, earning multiple awards in 2025, including the "Top 100 in China's Medical Health Industry Chain Service" and "Best Biotech Innovation Product Award" [1]. - Boya Life has been deeply engaged in cell technology for 16 years, operating under three brands: Boya Stem Cells, Boya Medical, and Boya Pharmaceutical, covering cell storage and health management, automated medical devices, and drug and medical technology research and development [3]. Industry Trends - Cell therapy, represented by life sciences, is viewed as a strategic, leading, disruptive, and forward-looking emerging industry, essential for driving technological progress and industrial upgrades in China [3]. - Exosomes, as key mediators of intercellular communication, have unique properties that make them suitable for applications in anti-aging, chronic disease intervention, and health maintenance [3]. Product Development - Boya Life has a robust pipeline in cell therapy, with nearly 20 cell medical technology and drug development projects underway, addressing major diseases in orthopedics, gynecology, and autoimmune systems, while also exploring anti-aging solutions [3][4]. - In the "Exosome+" sector, Boya provides GMP-grade stem cell exosome raw materials and commercial services, achieving positive progress in skin repair, inflammation repair, and degenerative diseases of the brain and eyes [4]. Market Position - Boya Stem Cells holds a 32% market share in China's placental mesenchymal stem cells, having provided cell storage and health management services to over 150,000 families [4]. - Boya Life leads the domestic cell industry in high-quality standards and standardization, certified by international organizations such as AABB and WHO [4]. Future Outlook - The company aims to continue driving the development of new productive forces represented by cell technology through ongoing innovation in technology research and product service models, contributing to public health improvement and the advancement of modern medicine [5].

Group 1 - The event "Quality Life 'Cell' Escort" was successfully held at the Jitao Medical Activity Center on June 10 [1] - Jitao Medical's General Manager Liu Kainian welcomed guests and introduced the company's development history and advantages in cell technology [3] - The event featured three main modules: exploration of cutting-edge technology, sharing of health knowledge, and personalized consultations, establishing a new paradigm for health management [4] Group 2 - Liu Tianjin, founder of Jitao Health and a PhD from the Shanghai Institute of Biochemistry and Cell Biology, shared insights on "Cell Technology and Life Health Management," highlighting breakthroughs in cell therapy for anti-aging, chronic disease intervention, and cancer prevention [5] - Club Chairman Wang Dawei emphasized the importance of health, happiness, and ambition as core elements of quality life, and expressed the club's commitment to providing customized health solutions in collaboration with Jitao Medical [7] - The event injected new momentum into the club's quality life sector, with plans to continuously integrate quality resources and innovate service models to enhance health and competitiveness in Weifang [9] Group 3 - Jitao Medical Technology Co., Ltd. is a technology-based enterprise founded by a postdoctoral researcher from the Chinese Academy of Sciences and the government-owned Hengjian Group, focusing on the development of immune cell and stem cell therapies, as well as early cancer diagnosis and intervention technologies [13] - The company has developed a tumor early diagnosis platform based on ctDNA methylation detection and has established a cell storage and preparation platform for precision treatment, recognized as one of the first provincial-level new research and development institutions in Shandong [13] - The regional cell tissue bank and preparation center in Weifang has a total investment of over 20 million yuan, featuring a public life science popularization museum and a 1,200 square meter cell storage and preparation center, adhering to international standards for clinical-grade and pharmaceutical-grade cell banks [14]